Literature DB >> 22129523

Diagnosis and management of type I and type V hyperlipoproteinemia.

Takanari Gotoda1, Koji Shirai, Takao Ohta, Junji Kobayashi, Shinji Yokoyama, Shinichi Oikawa, Hideaki Bujo, Shun Ishibashi, Hidenori Arai, Shizuya Yamashita, Mariko Harada-Shiba, Masaaki Eto, Toshio Hayashi, Hirohito Sone, Hiroaki Suzuki, Nobuhiro Yamada.   

Abstract

Both type I and type V hyperlipoproteinemia are characterized by severe hypertriglyceridemia due to an increase in chylomicrons. Type I hyperlipoproteinemia is caused by a decisive abnormality of the lipoprotein lipase (LPL)- apolipoprotein C-II system, whereas the cause of type V hyperlipoproteinemia is more complicated and more closely related to acquired environmental factors. Since the relationship of hypertriglyceridemia with atherosclerosis is not as clear as that of hypercholesterolemia, and since type I and V hyperlipoproteinemia are relatively rare, few guidelines for their diagnosis and treatment have been established; however, type I and V hyperlipoproteinemia are clinically important as underlying disorders of acute pancreatitis, and appropriate management is necessary to prevent or treat such complications. Against such a background, here we propose guidelines primarily concerning the diagnosis and management of type I and V hyperlipoproteinemia in Japanese.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129523     DOI: 10.5551/jat.10702

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  25 in total

1.  Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy.

Authors:  Lucy M Hinder; Andrea M Vincent; John M Hayes; Lisa L McLean; Eva L Feldman
Journal:  Exp Neurol       Date:  2012-10-08       Impact factor: 5.330

2.  First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma.

Authors:  Berna Solak; Rabia Oztas Kara; Seyyid Bilal Acikgoz; Mustafa Kosem
Journal:  BMJ Case Rep       Date:  2015-09-24

Review 3.  Chylomicronaemia--current diagnosis and future therapies.

Authors:  Amanda J Brahm; Robert A Hegele
Journal:  Nat Rev Endocrinol       Date:  2015-03-03       Impact factor: 43.330

Review 4.  How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention.

Authors:  Lane B Benes; Daniel J Brandt; Eric J Brandt; Michael H Davidson
Journal:  Curr Cardiol Rep       Date:  2018-10-17       Impact factor: 2.931

5.  A Case of Massive Hypertriglyceridemia in 6 Year Old Boy.

Authors:  Purvi Purohit; Daisy Khera; Praveen Sharma; Kuldeep Singh
Journal:  Indian J Clin Biochem       Date:  2016-11-16

6.  A Modern Approach to Dyslipidemia.

Authors:  Amanda J Berberich; Robert A Hegele
Journal:  Endocr Rev       Date:  2022-07-13       Impact factor: 25.261

Review 7.  Demystifying the management of hypertriglyceridaemia.

Authors:  Gerald F Watts; Esther M M Ooi; Dick C Chan
Journal:  Nat Rev Cardiol       Date:  2013-09-24       Impact factor: 32.419

Review 8.  Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Authors:  Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley
Journal:  Atherosclerosis       Date:  2017-10-20       Impact factor: 5.162

9.  Hypertriglyceridemia.

Authors:  Amanda Brahm; Robert A Hegele
Journal:  Nutrients       Date:  2013-03-22       Impact factor: 5.717

10.  Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects.

Authors:  Mathilde Di Filippo; Christophe Marçais; Sybil Charrière; Oriane Marmontel; Martine Broyer; Mireille Delay; Micheline Merlin; Axel Nollace; René Valéro; Michel Lagarde; Valérie Pruneta-Deloche; Philippe Moulin; Agnès Sassolas
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.